TY - JOUR
T1 - Neonatal hemochromatosis with εγδβ-thalassemia
T2 - a case report and analysis of serum iron regulators
AU - Tsuge, Mitsuru
AU - Kodera, Aya
AU - Sumitomo, Hiromi
AU - Araki, Tooru
AU - Yoshida, Ryuichi
AU - Yasui, Kazuya
AU - Sato, Hiroki
AU - Washio, Yosuke
AU - Washio, Kana
AU - Shigehara, Kenji
AU - Yashiro, Masato
AU - Yagi, Takahito
AU - Tsukahara, Hirokazu
N1 - Funding Information:
We would like to thank the pediatric surgeons at the National Hospital Organization Fukuyama Medical Center for their exclusion of biliary atresia. We thank Dr. Ito, Dr. Togawa, and Dr. Saito at the Department of Pediatrics at Nagoya City University Hospital, and Dr. Imagawa at the Department of Pediatrics at Tsukuba University for the genetic mutation analysis of hereditary infant cholestatic diseases. We also thank Dr. Yamashiro at Yamaguchi University and Dr. Hattori at Saiseikai Yamaguchi Hospital for genetic mutation analysis of εγδβ-thalassemia. We thank McProt Biotechnology Laboratories (http://www.mcprot.co.jp ) for the measurement of serum hepcidin-25 levels, Kazusa DNA Research Institute (https://www.kazusa.or.jp ) for gene mutation analysis of hereditary hemochromatosis, and Editage (http://www.editage.com ) for English language editing.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Neonatal hemochromatosis causes acute liver failure during the neonatal period, mostly due to gestational alloimmune liver disease (GALD). Thalassemia causes hemolytic anemia and ineffective erythropoiesis due to mutations in the globin gene. Although neonatal hemochromatosis and thalassemia have completely different causes, the coexistence of these diseases can synergistically exacerbate iron overload. We report that a newborn with εγδβ-thalassemia developed neonatal hemochromatosis, which did not respond to iron chelators and rapidly worsened, requiring living-donor liver transplantation. Case presentation: A 1-day-old Japanese boy with hemolytic anemia and targeted red blood cells was diagnosed with εγδβ-thalassemia by genetic testing, and required frequent red blood cell transfusions. At 2 months after birth, exacerbation of jaundice, grayish-white stool, and high serum ferritin levels were observed, and liver biopsy showed iron deposition in hepatocytes and Kupffer cells. Magnetic resonance imaging scans showed findings suggestive of iron deposits in the liver, spleen, pancreas, and bone marrow. The total amount of red blood cell transfusions administered did not meet the criteria for post-transfusion iron overload. Administration of an iron-chelating agent was initiated, but iron overload rapidly progressed to liver failure without improvement in jaundice and liver damage. He underwent living-donor liver transplantation from his mother, after which iron overload disappeared, and no recurrence of iron overload was observed. Immunohistochemical staining for C5b-9 in the liver was positive. Serum hepcidin levels were low and serum growth differentiation factor-15 levels were high prior to living-donor liver transplantation. Conclusions: We reported that an infant with εγδβ-thalassemia developed NH due to GALD, and that coexistence of ineffective erythropoiesis in addition to erythrocyte transfusions may have exacerbated iron overload. Low serum hepcidin levels, in this case, might have been caused by decreased hepcidin production arising from fetal liver damage due to neonatal hemochromatosis and increased hepcidin-inhibiting hematopoietic mediators due to the ineffective hematopoiesis observed in thalassemia.
AB - Background: Neonatal hemochromatosis causes acute liver failure during the neonatal period, mostly due to gestational alloimmune liver disease (GALD). Thalassemia causes hemolytic anemia and ineffective erythropoiesis due to mutations in the globin gene. Although neonatal hemochromatosis and thalassemia have completely different causes, the coexistence of these diseases can synergistically exacerbate iron overload. We report that a newborn with εγδβ-thalassemia developed neonatal hemochromatosis, which did not respond to iron chelators and rapidly worsened, requiring living-donor liver transplantation. Case presentation: A 1-day-old Japanese boy with hemolytic anemia and targeted red blood cells was diagnosed with εγδβ-thalassemia by genetic testing, and required frequent red blood cell transfusions. At 2 months after birth, exacerbation of jaundice, grayish-white stool, and high serum ferritin levels were observed, and liver biopsy showed iron deposition in hepatocytes and Kupffer cells. Magnetic resonance imaging scans showed findings suggestive of iron deposits in the liver, spleen, pancreas, and bone marrow. The total amount of red blood cell transfusions administered did not meet the criteria for post-transfusion iron overload. Administration of an iron-chelating agent was initiated, but iron overload rapidly progressed to liver failure without improvement in jaundice and liver damage. He underwent living-donor liver transplantation from his mother, after which iron overload disappeared, and no recurrence of iron overload was observed. Immunohistochemical staining for C5b-9 in the liver was positive. Serum hepcidin levels were low and serum growth differentiation factor-15 levels were high prior to living-donor liver transplantation. Conclusions: We reported that an infant with εγδβ-thalassemia developed NH due to GALD, and that coexistence of ineffective erythropoiesis in addition to erythrocyte transfusions may have exacerbated iron overload. Low serum hepcidin levels, in this case, might have been caused by decreased hepcidin production arising from fetal liver damage due to neonatal hemochromatosis and increased hepcidin-inhibiting hematopoietic mediators due to the ineffective hematopoiesis observed in thalassemia.
KW - Case report
KW - Gestational alloimmune liver disease
KW - Growth differentiation factor-15
KW - Hepcidin
KW - Ineffective erythropoiesis
KW - Liver transplantation
KW - Neonatal hemochromatosis
KW - Thalassemia
UR - http://www.scopus.com/inward/record.url?scp=85140874139&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140874139&partnerID=8YFLogxK
U2 - 10.1186/s12887-022-03706-3
DO - 10.1186/s12887-022-03706-3
M3 - Article
C2 - 36309641
AN - SCOPUS:85140874139
SN - 1471-2431
VL - 22
JO - BMC Pediatrics
JF - BMC Pediatrics
IS - 1
M1 - 622
ER -